- Home
- TTGT vs PROK Comparison
TTGT vs PROK Comparison
Compare TTGT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TTGT | PROK |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.2M | 331.2M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TTGT | PROK |
|---|---|---|
| Price | $3.92 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $10.75 | $7.40 |
| AVG Volume (30 Days) | 442.2K | ★ 633.3K |
| Earning Date | 03-11-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $2.75 | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $3.41 | $0.46 |
| 52 Week High | $14.82 | $7.13 |
Technical Indicators
Market Signals| Indicator | TTGT | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 32.76 |
| Support Level | $3.42 | $1.71 |
| Resistance Level | $5.88 | $2.58 |
| Average True Range (ATR) | 0.33 | 0.14 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 35.28 | 5.23 |
Price Performance
Historical ComparisonAbout TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.